QuidelOrtho Reports Third Quarter 2026 Financial Results
QuidelOrtho (QDEL) reported Q3 2026 revenue of $619M, down 12% YoY. Excluding respiratory, China, and U.S. Donor Screening, revenue grew 2-3%. Labs revenue declined 6% due to China pricing changes, but grew 3-4% outside China. Point of Care revenue dropped 27% due to a softer respiratory season. The company launched a cost transformation program expected to save $80M annually in 2027. Full-year 2026 guidance was narrowed, with revenue now expected between $2.52B-$2.54B.



